Biomarin Pharmaceutical Inc. (BMRN)
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study
BioMarin shares fall after BMN 401 meets a biomarker goal but misses a key radiographic endpoint in a late-stage ENPP1 deficiency study.
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition
BioMarin Pharmaceutical remains a "Strong Buy," driven by pipeline progress, strategic acquisitions, and robust revenue guidance. BMRN's acquisition of Amicus Therapeutics adds GALAFOLD and POMBILITI + OPFOLDA, boosting 2026 revenue guidance to $3.825–$3.925 billion and targeting 20% YoY growth. VOXZOGO expansion into hypochondroplasia and ongoing clinical trials represent major catalysts, with topline Phase 3 data expected in Q2 2026.
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised
BMRN misses Q1 EPS estimates despite a revenue beat, as charges and higher costs weigh on profits, while new Amicus deal lifts the 2026 outlook.
BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call Transcript
Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
BioMarin Pharmaceutical (BMRN) Q1 Earnings Lag Estimates
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.13 per share a year ago.
BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy
BioMarin (BMRN) has declined over 12% since January 2025, despite prior optimism. The investment thesis centers on the potential of VOXZOGO and Amicus's two approved therapies to drive future upside. Current share weakness may present a buying opportunity given VOXZOGO's prospects.
BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
BioMarin stops mid-stage trials of bone disorder treatment
BioMarin Pharmaceutical will discontinue mid-stage trials of its bone disorder treatment after reports of several cases of patients' hip joint slipping out of place, the drugmaker said on Monday, sending its shares down 4%.
BioMarin Pharmaceutical Inc. (BMRN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Leerink Global Healthcare Conference 2026 Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Leerink Global Healthcare Conference 2026 Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
